The device was designed to treat patients facing a heightened risk of recurrent stroke.

Overall, mitral valve surgery after TEER was associated with a 30-day mortality rate of 16.6% and one-year mortality rate of 31.3%.

Recent research published in JAMA Cardiology caught the agency's attention.

The next-generation devices were designed to be used without blood-thinners. 

The study's authors examined data from men and women who underwent TEER with the MitraClip device in addition to guideline-directed medical therapy. 

CardioSmart, an online resource for both patients and clinicians, has a new editor.